SCHEMBL17015705

SCHEMBL17015705

c1ccc(-c2ccc(-n3ccc4c3ccc3c5ccccc5n(-c5cccc(-n6c7ccccc7c7ccccc76)c5)c34)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ATM Q13315 1/20 0.41
HTR7 P34969 1/20 0.36
HDAC4 P56524 1/20 0.34
WNK1 Q9H4A3 1/20 0.32
EDNRB P24530 1/20 0.32
EDNRA P25101 1/20 0.32
MAOB P27338 1/20 0.32
KMT2A Q03164 3/20 0.32
IL1R1 P14778 1/20 0.32
MEN1 O00255 2/20 0.31
GAA P10253 1/20 0.31
RXRA P19793 1/20 0.31
RXRB P28702 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
DUSP3 P51452 1/20 0.31
ALKBH5 Q6P6C2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015708 0.96 KDM4E (0.39) L3MBTL1KDM4EATMHTR7HDAC4
SCHEMBL17015711 0.96 KDM4E (0.39) L3MBTL1KDM4EATMHTR7HDAC4
SCHEMBL17015710 0.96 KDM4E (0.39) L3MBTL1KDM4EATMHTR7HDAC4
SCHEMBL17015242 0.95 KDM4E (0.40) L3MBTL1KDM4EATMHTR7HDAC4
SCHEMBL17015237 0.95 KDM4E (0.40) L3MBTL1KDM4EATMHTR7HDAC4
SCHEMBL17015238 0.95 KDM4E (0.40) L3MBTL1KDM4EATMHTR7HDAC4
SCHEMBL17015233 0.94 KDM4E (0.47) L3MBTL1KDM4EATMKMT2AALDH1A1
SCHEMBL17015707 0.93 KDM4E (0.38) L3MBTL1KDM4EATMHTR7HDAC4
SCHEMBL15684055 0.92 ATM (0.40) L3MBTL1KDM4EATMHTR7WNK1
SCHEMBL15632306 0.92 L3MBTL1 (0.50) L3MBTL1KDM4EATMHTR7HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 L3MBTL1 533/4885KDM4E 1286/4885ATM 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.